Larimar Therapeutics LRMR
NASDAQ LRMR
$2.42 -0.02 (-0.82%)
At close: Oct 21, 2026 · 4:00 PM EDT

Larimar Therapeutics (LRMR) Cash from Restructuring (2019 - 2020)

Updated

Larimar Therapeutics' Cash from Restructuring came in at -$1.73 million for Q1 2020.

Analysis

Larimar Therapeutics (LRMR) Cash from Restructuring (2019 - 2020) Analysis & Trends

For FY2019, Larimar Therapeutics' Cash from Restructuring was $2.71 million.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn
10 Larimar Therapeutics 252.95 Mn -354.12 Mn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2020 -1.73 Mn
Dec 31, 2019 -910,000.00
API Access

Larimar Therapeutics Cash from Restructuring API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=cash-from-restructuring&ticker=LRMR&period=max&api_key=YOUR_API_KEY